PubMed (MeSH Keyword) for id: 6918638

Year	Number of Results
2003	1
2006	3
2007	8
2008	10
2009	9
2010	10
2011	13
2012	10
2013	15
2014	14
2015	20
2016	21
2017	16
2018	11
2019	18
2020	13
2021	7
2022	4
2023	7
2024	2

1

The Utility of Spectroscopic MRI in Stereotactic Biopsy and Radiotherapy Guidance in Newly Diagnosed Glioblastoma.

Rejimon AC, Ramesh KK, Trivedi AG, Huang V, Schreibmann E, Weinberg BD, Kleinberg LR, Shu HG, Shim H, Olson JJ. Rejimon AC, et al. Tomography. 2024 Mar 20;10(3):428-443. doi: 10.3390/tomography10030033. Tomography. 2024. PMID: 38535775 Free PMC article.

2

Investigation of the effect of belinostat on MCF-7 breast cancer stem cells via the Wnt, Notch, and Hedgehog signaling pathway.

Tuncer Z, Kurar E, Duran T. Tuncer Z, et al. Saudi Med J. 2024 Feb;45(2):121-127. doi: 10.15537/smj.2024.45.2.20230478. Saudi Med J. 2024. PMID: 38309728 Free article.

3

Belinostat loaded lipid-polymer hybrid nanoparticulate delivery system for breast cancer: improved pharmacokinetics and biodistribution in a tumor model.

Pradyuth KS, Salunkhe SA, Singh AK, Chitkara D, Mittal A. Pradyuth KS, et al. J Mater Chem B. 2023 Nov 22;11(45):10859-10872. doi: 10.1039/d3tb01317k. J Mater Chem B. 2023. PMID: 37938124

4

A Novel High-Content Screening Assay Identified Belinostat as Protective in a FSGS-Like Zebrafish Model.

Schindler M, Siegerist F, Lange T, Simm S, Bach SM, Klawitter M, Gehrig J, Gul S, Endlich N. Schindler M, et al. J Am Soc Nephrol. 2023 Dec 1;34(12):1977-1990. doi: 10.1681/ASN.0000000000000235. Epub 2023 Sep 27. J Am Soc Nephrol. 2023. PMID: 37752628

5

Anticancer clinical efficiency and stochastic mechanisms of belinostat.

El Omari N, Bakrim S, Khalid A, Albratty M, Abdalla AN, Lee LH, Goh KW, Ming LC, Bouyahya A. El Omari N, et al. Biomed Pharmacother. 2023 Sep;165:115212. doi: 10.1016/j.biopha.2023.115212. Epub 2023 Aug 2. Biomed Pharmacother. 2023. PMID: 37541175 Free article. Review.

6

Mutant Isocitrate Dehydrogenase 1 Expression Enhances Response of Gliomas to the Histone Deacetylase Inhibitor Belinostat.

Chang CM, Ramesh KK, Huang V, Gurbani S, Kleinberg LR, Weinberg BD, Shim H, Shu HG. Chang CM, et al. Tomography. 2023 May 4;9(3):942-954. doi: 10.3390/tomography9030077. Tomography. 2023. PMID: 37218937 Free PMC article.

7

Histone deacetylase inhibitor belinostat regulates metabolic reprogramming in killing KRAS-mutant human lung cancer cells.

Peter RM, Sarwar MS, Mostafa SZ, Wang Y, Su X, Kong AN. Peter RM, et al. Mol Carcinog. 2023 Aug;62(8):1136-1146. doi: 10.1002/mc.23551. Epub 2023 May 5. Mol Carcinog. 2023. PMID: 37144836

8

Phase 1 study of belinostat and adavosertib in patients with relapsed or refractory myeloid malignancies.

Shafer D, Kagan AB, Rudek MA, Kmieciak M, Tombes MB, Shrader E, Bandyopadhyay D, Hudson D, Sankala H, Weir C, Lancet JE, Grant S. Shafer D, et al. Cancer Chemother Pharmacol. 2023 Mar;91(3):281-290. doi: 10.1007/s00280-023-04511-0. Epub 2023 Mar 2. Cancer Chemother Pharmacol. 2023. PMID: 36864346 Free PMC article. Clinical Trial.

9

Anti-proliferative, pro-apototic and anti-migratory properties of HDAC inhibitor PXD-101 on osteosarcoma cell lines.

Rossi M, De Martino V, Di Giuseppe L, Battafarano G, Di Gregorio J, Terreri S, Marampon F, Minisola S, Del Fattore A. Rossi M, et al. Arch Biochem Biophys. 2023 Jan 15;734:109489. doi: 10.1016/j.abb.2022.109489. Epub 2022 Dec 13. Arch Biochem Biophys. 2023. PMID: 36526001

10

Belinostat (PXD101) resists UVB irradiation-induced cellular senescence and skin photoaging.

Jia HJ, Ge Y, Xia J, Shi YL, Wang XB. Jia HJ, et al. Biochem Biophys Res Commun. 2022 Oct 30;627:122-129. doi: 10.1016/j.bbrc.2022.08.038. Epub 2022 Aug 17. Biochem Biophys Res Commun. 2022. PMID: 36030653

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

177 results

Results by year